GSK plc

GSK

GB00BN7SWP63

Pharmaceuticals

Market Closed - London S.E. Other stock markets 09:05:12 10/07/2026 pm IST			5-day change	1st Jan Change
1,961.50 ^GBX	+0.10%		-2.66%	+7.51%

10/07	GSK says Ris-Rez meets primary endpoint in phase 3 lung cancer trial	AN
10/07	GSK, Hansoh's targeted cancer drug hits main survival goal in China trial	RE

GSK : Deutsche Bank reaffirms its Neutral rating

Published on 06/02/2026 at 01:13 pm IST

MarketScreener with dpa-AFX Analyser

Add MarketScreener to your sources

GSK PLC

+0.10%

Deutsche Bank analyst Emmanuel Papadakis maintains his Neutral opinion on the stock. The target price is unchanged and still at GBX 1900.

Add MarketScreener to your sources

Latest news about GSK plc

10/07	GSK says Ris-Rez meets primary endpoint in phase 3 lung cancer trial	AN
10/07	GSK, Hansoh's targeted cancer drug hits main survival goal in China trial	RE
10/07	GSK Licensor Hansoh Reports Positive Phase 3 Results for Risvutatug Rezetecan in China	MT
10/07	GSK's Antibody-drug Conjugate for Small-cell Lung Cancer Meets Primary Endpoint in Late-stage China Study	MT
09/07	Gsk plc Announces Appointment of Roy Jakobs to Non-Executive Director, Effective July 13, 2026	CI
09/07	Wall Street Ignores the Sirens
09/07	GSK adds Royal Philips' Chief Executive Jakobs to board	AN
09/07	GSK : Deutsche Bank remains Neutral	ZD
09/07	Computacenter gets two price target hikes	AN
09/07	Oil keeps markets on edge
09/07	UK Stocks-Factors to watch on July 9	RE
08/07	European Stocks Close Sharply Lower in Wednesday Trading; Oil Prices Spike as US-Iran War Reignites	MT
08/07	Trump Breaks the Calm
08/07	GSK, Sino Biopharmaceutical Unit Expand Collaboration to Cover Two GSK Respiratory Therapies	MT
08/07	European Midday Briefing : Shares Fall, Oil Rises as Trump Declares Ceasefire Over	DJ

GSK plc is the world's No. 2 pharmaceutical group. Net sales break down by family of products as follows: - pharmaceutical products (41.3%): intended mainly for HIV infection (57% of net sales), immune system disorders and respiratory diseases (28.3%), and cancer (14.7%); - OTC and parapharmaceutical medicine (30.7%); - vaccines (28%). Net sales are distributed geographically as follows: the United Kingdom (2.1%), Europe (21%), the United States (51.6%), and other (25.3%).

Employees

66,841

Sector

Pharmaceuticals

Calendar

28/07 - Earnings release - Q2 2026

More about the company